RegenXBio (RGNX)
NASDAQ:RGNX
Want to see RGNX full AI Analyst Report?
RGNX Stock Chart & Stats
$9.49
-$0.26(-3.11%)
At close: 4:00 PM EST
$9.49
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$6.89 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)734.14K
Market Cap
$433.58M
Enterprise Value$659.64M
Total Cash (Recent Filing)$230.07M
Total Debt (Recent Filing)$260.52M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
May 06, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding51,617,233
10 Day Avg. Volume544,913
30 Day Avg. Volume734,138
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit7.32
Enterprise Value/Ebitda-4.53
Forecast
1Y Price Target
$30.60Price Target Upside222.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$252.45M
Bulls Say, Bears Say
Bulls Say
Financial Runway And Partner SupportSolid cash resources, committed partner funding and stronger-than-expected licensing and royalty revenue could extend the development runway and lower near-term financing risk.
Manufacturing And Regulatory AlignmentCommercial-scale manufacturing of RGX-202 and plans to seek pre-submission alignment with regulators reduce execution risk around a potential regulatory filing and commercial launch.
Pivotal Trial ReadoutsTopline pivotal readouts for the Duchenne RGX-202 program and late-stage sura-vec retinal studies could enable regulatory filings and meaningful commercial opportunities if efficacy and safety are confirmed.
Bears Say
Clinical Variability And Limited Sample SizeSubstantial variability in patient responses and small early sample sizes increase uncertainty about treatment effectiveness and make it harder to build conviction ahead of pivotal trials.
Regulatory Uncertainty From Agency FeedbackA complete response letter highlighting uncertainty in target population definition, control comparability and surrogate endpoint relevance has created a regulatory overhang and complicates approval pathways.
Safety Findings And Clinical HoldsDetection of a brain tumor in a related program and evidence of viral vector integration near cancer-related genes prompted clinical holds, creating material safety uncertainty for linked programs.
RegenXBio News
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $6.89 and its highest was $16.19 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $433.58M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is May 06, 2026 which is in 5 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Mar 05, 2026. The company reported -$1.3 earnings per share for the quarter, missing the consensus estimate of -$0.956 by -$0.344.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -1.34.
How many shares outstanding does RegenXBio have?
RegenXBio has 51,617,233 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.3 in its last earnings report, missing expectations of -$0.956. Following the earnings report the stock price went down -4.595%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.60 (222.44% Upside)
$30.60 (222.44% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 162.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
59.76%
12-Months-Change
Fundamentals
Return on Equity
-103.12%
Trailing 12-Months
Asset Growth
-2.78%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong development and commercial catalysts: completed pivotal enrollment in Duchenne with differentiated efficacy and safety signals for RGX-202, substantial progress and promising outcomes in the Cirovec retinal programs (including large reductions in anti-VEGF injections and durable responses), an active AbbVie collaboration with a near-term $100M milestone, and solid revenue/financing transactions that support a runway into early 2027. Offsetting these positives are material regulatory setbacks in the MPS programs (CRL and clinical holds) driven by an AAV integration–associated tumor in one patient and biomarker/assay issues, plus higher R&D spend and reliance on milestone/monetization proceeds. Overall, the company appears to have multiple high-value, late-stage assets and funding pathways, but faces meaningful program-specific safety and regulatory risks that will need to be resolved.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$30.60
▲(222.44% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.79% Insiders
17.50% Mutual Funds
2.76% Other Institutional Investors
56.03% Public Companies and Individual Investors